CycloZ bridges this gap by dual mechanisms: it mitigates TLR4-driven immune triggers of allergic asthma and reduces downstream Th2-mediated inflammation, notably decreasing cytokines like IL-4 and IL-13. The gene discussed is IL13; the disease is allergic asthma.